Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Pediatric Drugs
Published in: Pediatric Drugs 6/2023

Open Access 02-09-2023 | Bronchial Asthma | Review Article

Developments in the Management of Severe Asthma in Children and Adolescents: Focus on Dupilumab and Tezepelumab

Authors: Yoni E. van Dijk, Niels W. Rutjes, Korneliusz Golebski, Havva Şahin, Simone Hashimoto, Anke-Hilse Maitland-van der Zee, Susanne J. H. Vijverberg

Published in: Pediatric Drugs | Issue 6/2023

Login to get access

Abstract

Severe asthma in children and adolescents exerts a substantial health, financial, and societal burden. Severe asthma is a heterogeneous condition with multiple clinical phenotypes and underlying inflammatory patterns that might be different in individual patients. Various add-on treatments have been developed to treat severe asthma, including monoclonal antibodies (biologics) targeting inflammatory mediators. Biologics that are currently approved to treat children (≥ 6 years of age) or adolescents (≥ 12 years of age) with severe asthma include: anti-immunoglobulin E (omalizumab), anti-interleukin (IL)-5 (mepolizumab), anti-IL5 receptor (benralizumab), anti-IL4/IL13 receptor (dupilumab), and antithymic stromal lymphopoietin (TSLP) (tezepelumab). However, access to these targeted treatments varies across countries and relies on few and crude indicators. There is a need for better treatment stratification to guide which children might benefit from these treatments. In this narrative review we will assess the most recent developments in the treatment of severe pediatric asthma, as well as potential biomarkers to assess treatment efficacy for this patient population.
Literature
1.
Fleming L, Murray C, Bansal AT, Hashimoto S, Bisgaard H, Bush A, et al. The burden of severe asthma in childhood and adolescence: results from the paediatric U-BIOPRED cohorts. Eur Respir J. 2015;46(5):1322–33.PubMedCrossRef
2.
Moonie SA, Sterling DA, Figgs L, Castro M. Asthma status and severity affects missed school days. J Sch Health. 2006;76(1):18–24.PubMedCrossRef
3.
van den Bemt L, Kooijman S, Linssen V, Lucassen P, Muris J, Slabbers G, et al. How does asthma influence the daily life of children? Results of focus group interviews. Health Qual Life Outcomes. 2010;8:5.PubMedPubMedCentralCrossRef
4.
Montalbano L, Ferrante G, Montella S, Cilluffo G, Di Marco A, Bozzetto S, et al. Relationship between quality of life and behavioural disorders in children with persistent asthma: a Multiple Indicators Multiple Causes (MIMIC) model. Sci Rep. 2020;10(1):6957.PubMedPubMedCentralCrossRef
5.
6.
Kachroo P, Stewart ID, Kelly RS, Stav M, Mendez K, Dahlin A, et al. Metabolomic profiling reveals extensive adrenal suppression due to inhaled corticosteroid therapy in asthma. Nat Med. 2022;28(4):814–22.PubMedPubMedCentralCrossRef
7.
Axelsson I, Naumburg E, Prietsch SO, Zhang L. Inhaled corticosteroids in children with persistent asthma: effects of different drugs and delivery devices on growth. Cochrane Database Syst Rev. 2019;6(6):Cd010126.
8.
9.
Sweeney J, Patterson CC, Menzies-Gow A, Niven RM, Mansur AH, Bucknall C, et al. Comorbidity in severe asthma requiring systemic corticosteroid therapy: cross-sectional data from the Optimum Patient Care Research Database and the British Thoracic Difficult Asthma Registry. Thorax. 2016;71(4):339–46.PubMedCrossRef
10.
11.
Bush A, Fitzpatrick AM, Saglani S, Anderson WC, Szefler SJ. Difficult-to-treat asthma management in school-age children. J Allergy Clin Immunol Pract. 2022;10(2):359–75.PubMedCrossRef
12.
Bagnasco D, Paggiaro P, Latorre M, Folli C, Testino E, Bassi A, et al. Severe asthma: One disease and multiple definitions. World Allergy Organ J. 2021;14(11): 100606.PubMedPubMedCentralCrossRef
13.
Bousquet J, Mantzouranis E, Cruz AA, Aït-Khaled N, Baena-Cagnani CE, Bleecker ER, et al. Uniform definition of asthma severity, control, and exacerbations: document presented for the World Health Organization Consultation on Severe Asthma. J Allergy Clin Immunol. 2010;126(5):926–38.PubMedCrossRef
14.
Bossley CJ, Fleming L, Ullmann N, Gupta A, Adams A, Nagakumar P, et al. Assessment of corticosteroid response in pediatric patients with severe asthma by using a multidomain approach. J Allergy Clin Immunol. 2016;138(2):413-20.e6.PubMedCrossRef
15.
Cook J, Beresford F, Fainardi V, Hall P, Housley G, Jamalzadeh A, et al. Managing the pediatric patient with refractory asthma: a multidisciplinary approach. J Asthma Allergy. 2017;10:123–30.PubMedPubMedCentralCrossRef
16.
17.
Alizadeh Bahmani AH, Abdel-Aziz MI, Maitland-van der Zee AH, Vijverberg SJH. Recent advances in the treatment of childhood asthma: a clinical pharmacology perspective. Expert Rev Clin Pharmacol. 2022;15(10):1165–76.
18.
Principe S, Vijverberg SJH, Abdel-Aziz MI, Scichilone N, Maitland-van der Zee AH. Precision medicine in asthma therapy. Handb Exp Pharmacol. 2022.
19.
Golebski K, Dankelman LHM, Björkander S, Bønnelykke K, Brinkman P, Deschildre A, et al. Expert meeting report: towards a joint European roadmap to address the unmet needs and priorities of paediatric asthma patients on biologic therapy. ERJ Open Res. 2021;7(4).
20.
Holguin F, Cardet JC, Chung KF, Diver S, Ferreira DS, Fitzpatrick A, et al. Management of severe asthma: a European Respiratory Society/American Thoracic Society guideline. Eur Resp J. 2020;55(1).
21.
Licari A, Manti S, Castagnoli R, Parisi GF, Salpietro C, Leonardi S, et al. Targeted therapy for severe asthma in children and adolescents: current and future perspectives. Paediatr Drugs. 2019;21(4):215–37.PubMedCrossRef
22.
Licari A, Castagnoli R, Marseglia A, Olivero F, Votto M, Ciprandi G, et al. Dupilumab to treat type 2 inflammatory diseases in children and adolescents. Paediatr Drugs. 2020;22(3):295–310.PubMedCrossRef
23.
Fleming L, Tsartsali L, Wilson N, Regamey N, Bush A. Sputum inflammatory phenotypes are not stable in children with asthma. Thorax. 2012;67(8):675–81.PubMedCrossRef
24.
Pijnenburg MW, Frey U, De Jongste JC, Saglani S. Childhood asthma: pathogenesis and phenotypes. Eur Resp J. 2022;59(6).
25.
Anderson GP. Endotyping asthma: new insights into key pathogenic mechanisms in a complex, heterogeneous disease. Lancet. 2008;372(9643):1107–19.PubMedCrossRef
26.
Diamant Z, Vijverberg S, Alving K, Bakirtas A, Bjermer L, Custovic A, et al. Towards clinically applicable biomarkers for asthma—an EAACI position paper. Allergy. 2019.
27.
Heijink IH, Kies PM, Kauffman HF, Postma DS, van Oosterhout AJ, Vellenga E. Down-regulation of E-cadherin in human bronchial epithelial cells leads to epidermal growth factor receptor-dependent Th2 cell-promoting activity. J Immunol. 2007;178(12):7678–85.PubMedCrossRef
28.
Wawrzyniak P, Wawrzyniak M, Wanke K, Sokolowska M, Bendelja K, Rückert B, et al. Regulation of bronchial epithelial barrier integrity by type 2 cytokines and histone deacetylases in asthmatic patients. J Allergy Clin Immunol. 2017;139(1):93–103.PubMedCrossRef
29.
Striz I, Golebski K, Strizova Z, Loukides S, Bakakos P, Hanania NA, et al. New insights into the pathophysiology and therapeutic targets of asthma and comorbid chronic rhinosinusitis with or without nasal polyposis. Clin Sci (Lond). 2023;137(9):727–53.PubMedCrossRef
30.
Golebski K, Röschmann KI, Toppila-Salmi S, Hammad H, Lambrecht BN, Renkonen R, et al. The multi-faceted role of allergen exposure to the local airway mucosa. Allergy. 2013;68(2):152–60.PubMedCrossRef
31.
Golebski K, Layhadi JA, Sahiner U, Steveling-Klein EH, Lenormand MM, Li RCY, et al. Induction of IL-10-producing type 2 innate lymphoid cells by allergen immunotherapy is associated with clinical response. Immunity. 2021;54(2):291-307.e7.PubMedCrossRef
32.
van der Ploeg EK, Golebski K, van Nimwegen M, Fergusson JR, Heesters BA, Martinez-Gonzalez I, et al. Steroid-resistant human inflammatory ILC2s are marked by CD45RO and elevated in type 2 respiratory diseases. Sci Immunol. 2021;6(55).
33.
34.
Szefler SJ, Martin RJ, King TS, Boushey HA, Cherniack RM, Chinchilli VM, et al. Significant variability in response to inhaled corticosteroids for persistent asthma. J Allergy Clin Immunol. 2002;109(3):410–8.PubMedCrossRef
35.
36.
Hondowicz BD, An D, Schenkel JM, Kim KS, Steach HR, Krishnamurty AT, et al. Interleukin-2-dependent allergen-specific tissue-resident memory cells drive asthma. Immunity. 2016;44(1):155–66.PubMedCrossRef
37.
Bossley CJ, Fleming L, Gupta A, Regamey N, Frith J, Oates T, et al. Pediatric severe asthma is characterized by eosinophilia and remodeling without T(H)2 cytokines. J Allergy Clin Immunol. 2012;129(4):974-82.e13.PubMedPubMedCentralCrossRef
38.
Su MW, Lin WC, Tsai CH, Chiang BL, Yang YH, Lin YT, et al. Childhood asthma clusters reveal neutrophil-predominant phenotype with distinct gene expression. Allergy. 2018;73(10):2024–32.PubMedCrossRef
39.
Wisniewski JA, Muehling LM, Eccles JD, Capaldo BJ, Agrawal R, Shirley DA, et al. TH1 signatures are present in the lower airways of children with severe asthma, regardless of allergic status. J Allergy Clin Immunol. 2018;141(6):2048-60.e13.PubMedCrossRef
40.
Crisford H, Sapey E, Rogers GB, Taylor S, Nagakumar P, Lokwani R, et al. Neutrophils in asthma: the good, the bad and the bacteria. Thorax. 2021;76(8):835–44.PubMedCrossRef
41.
Moore WC, Hastie AT, Li X, Li H, Busse WW, Jarjour NN, et al. Sputum neutrophil counts are associated with more severe asthma phenotypes using cluster analysis. J Allergy Clin Immunol. 2014;133(6):1557-63.e5.PubMedCrossRef
42.
Louis R, Lau LC, Bron AO, Roldaan AC, Radermecker M, Djukanović R. The relationship between airways inflammation and asthma severity. Am J Respir Crit Care Med. 2000;161(1):9–16.PubMedCrossRef
43.
Shaw DE, Berry MA, Hargadon B, McKenna S, Shelley MJ, Green RH, et al. Association between neutrophilic airway inflammation and airflow limitation in adults with asthma. Chest. 2007;132(6):1871–5.PubMedCrossRef
44.
Cowan DC, Cowan JO, Palmay R, Williamson A, Taylor DR. Effects of steroid therapy on inflammatory cell subtypes in asthma. Thorax. 2010;65(5):384–90.PubMedCrossRef
45.
46.
Shimoda T, Obase Y, Nagasaka Y, Nakano H, Kishikawa R, Iwanaga T. Airway inflammation phenotype prediction in asthma patients using lung sound analysis with fractional exhaled nitric oxide. Allergol Int. 2017;66(4):581–5.PubMedCrossRef
47.
Green BJ, Wiriyachaiporn S, Grainge C, Rogers GB, Kehagia V, Lau L, et al. Potentially pathogenic airway bacteria and neutrophilic inflammation in treatment resistant severe asthma. PLoS ONE. 2014;9(6): e100645.PubMedPubMedCentralCrossRef
48.
Sze E, Bhalla A, Nair P. Mechanisms and therapeutic strategies for non-T2 asthma. Allergy. 2020;75(2):311–25.PubMedCrossRef
49.
Kuipers I, Louis R, Manise M, Dentener MA, Irvin CG, Janssen-Heininger YM, et al. Increased glutaredoxin-1 and decreased protein S-glutathionylation in sputum of asthmatics. Eur Resp J. 2013;41(2):469–72.CrossRef
50.
Di Cicco M, Ghezzi M, Kantar A, Song WJ, Bush A, Peroni D, et al. Pediatric obesity and severe asthma: targeting pathways driving inflammation. Pharmacol Res. 2023;188: 106658.PubMedCrossRef
51.
Reyes-Angel J, Kaviany P, Rastogi D, Forno E. Obesity-related asthma in children and adolescents. Lancet Child Adolesc Health. 2022;6(10):713–24.PubMedCrossRef
52.
53.
Platts-Mills TA. The role of immunoglobulin E in allergy and asthma. Am J Respir Crit Care Med. 2001;164(8 Pt 2):S1-5.PubMedCrossRef
54.
Oliver JM, Tarleton CA, Gilmartin L, Archibeque T, Qualls CR, Diehl L, et al. Reduced FcepsilonRI-mediated release of asthma-promoting cytokines and chemokines from human basophils during omalizumab therapy. Int Arch Allergy Immunol. 2010;151(4):275–84.PubMedCrossRef
55.
Fu Z, Xu Y, Cai C. Efficacy and safety of omalizumab in children with moderate-to-severe asthma: a meta-analysis. J Asthma. 2021;58(10):1350–8.PubMedCrossRef
56.
57.
Pavord ID, Bel EH, Bourdin A, Chan R, Han JK, Keene ON, et al. From DREAM to REALITI-A and beyond: mepolizumab for the treatment of eosinophil-driven diseases. Allergy. 2022;77(3):778–97.PubMedCrossRef
58.
Flood-Page P, Menzies-Gow A, Phipps S, Ying S, Wangoo A, Ludwig MS, et al. Anti-IL-5 treatment reduces deposition of ECM proteins in the bronchial subepithelial basement membrane of mild atopic asthmatics. J Clin Investig. 2003;112(7):1029–36.PubMedPubMedCentralCrossRef
59.
Khatri S, Moore W, Gibson PG, Leigh R, Bourdin A, Maspero J, et al. Assessment of the long-term safety of mepolizumab and durability of clinical response in patients with severe eosinophilic asthma. J Allergy Clin Immunol. 2019;143(5):1742-51.e7.PubMedCrossRef
60.
Kolbeck R, Kozhich A, Koike M, Peng L, Andersson CK, Damschroder MM, et al. MEDI-563, a humanized anti-IL-5 receptor alpha mAb with enhanced antibody-dependent cell-mediated cytotoxicity function. J Allergy Clin Immunol. 2010;125(6):1344-53.e2.PubMedCrossRef
61.
Korn S, Bourdin A, Chupp G, Cosio BG, Arbetter D, Shah M, et al. Integrated safety and efficacy among patients receiving benralizumab for up to 5 years. J Allergy Clin Immunol Pract. 2021;9(12):4381-92.e4.PubMedCrossRef
62.
Porsbjerg CM, Menzies-Gow AN, Tran TN, Murray RB, Unni B, Audrey Ang SL, et al. Global variability in administrative approval prescription criteria for biologic therapy in severe asthma. J Allergy Clin Immunol Pract. 2022;10(5):1202-16.e23.PubMedCrossRef
63.
Santos-Valente E, Buntrock-Döpke H, Abou Taam R, Arasi S, Bakirtas A, Lozano Blasco J, et al. Biologicals in childhood severe asthma: the European PERMEABLE survey on the. ERJ Open Res. 2021;7(3).
64.
Rusconi F, Fernandes RM, Pijnenburg MWH, Grigg J. The Severe Paediatric Asthma Collaborative in Europe (SPACE) ERS Clinical Research Collaboration: enhancing participation of children with asthma in therapeutic trials of new biologics and receptor blockers. Eur Resp J. 2018;52(4).
65.
Mathioudakis AG, Miligkos M, Boccabella C, Alimani GS, Custovic A, Deschildre A, et al. Management of asthma in childhood: study protocol of a systematic evidence update by the Paediatric Asthma in Real Life (PeARL) Think Tank. BMJ Open. 2021;11(7): e048338.PubMedPubMedCentralCrossRef
66.
67.
Elo LL, Järvenpää H, Tuomela S, Raghav S, Ahlfors H, Laurila K, et al. Genome-wide profiling of interleukin-4 and STAT6 transcription factor regulation of human Th2 cell programming. Immunity. 2010;32(6):852–62.PubMedCrossRef
68.
Wenzel S, Castro M, Corren J, Maspero J, Wang L, Zhang B, et al. Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting β2 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial. Lancet. 2016;388(10039):31–44.PubMedCrossRef
69.
Rabe KF, Nair P, Brusselle G, Maspero JF, Castro M, Sher L, et al. Efficacy and safety of dupilumab in glucocorticoid-dependent severe asthma. N Engl J Med. 2018;378(26):2475–85.PubMedCrossRef
70.
Castro M, Corren J, Pavord ID, Maspero J, Wenzel S, Rabe KF, et al. Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma. N Engl J Med. 2018;378(26):2486–96.PubMedCrossRef
71.
Blaiss MS, Castro M, Chipps BE, Zitt M, Panettieri RA Jr, Foggs MB. Guiding principles for use of newer biologics and bronchial thermoplasty for patients with severe asthma. Ann Allergy Asthma Immunol. 2017;119(6):533–40.PubMedCrossRef
72.
Maspero JF, FitzGerald JM, Pavord ID, Rice MS, Maroni J, Rowe PJ, et al. Dupilumab efficacy in adolescents with uncontrolled, moderate-to-severe asthma: LIBERTY ASTHMA QUEST. Allergy. 2021;76(8):2621–4.PubMedCrossRef
73.
Bacharier LB, Maspero JF, Katelaris CH, Fiocchi AG, Gagnon R, de Mir I, et al. Dupilumab in children with uncontrolled moderate-to-severe asthma. N Engl J Med. 2021;385(24):2230–40.PubMedCrossRef
74.
Jackson DJ, Bacharier LB, Phipatanakul W, Sher L, Domingo C, Papadopoulos N, et al. Dupilumab pharmacokinetics and effect on type 2 biomarkers in children with moderate-to-severe asthma. Annals Allergy Asthma Immunol. 2023.
75.
NCT05347771 CgI. Prevention of asthma exacerbations using dupilumab in urban children and adolescents (PANDA).
76.
77.
Golebski K, van Tongeren J, van Egmond D, de Groot EJ, Fokkens WJ, van Drunen CM. Specific induction of TSLP by the viral RNA analogue Poly(I:C) in primary epithelial cells derived from nasal polyps. PLoS ONE. 2016;11(4): e0152808.PubMedPubMedCentralCrossRef
78.
Furci F, Murdaca G, Pelaia C, Imbalzano E, Pelaia G, Caminati M, et al. TSLP and HMGB1: inflammatory targets and potential biomarkers for precision medicine in asthma and COPD. Biomedicines. 2023;11(2).
79.
Ebina-Shibuya R, Leonard WJ. Role of thymic stromal lymphopoietin in allergy and beyond. Nat Rev Immunol. 2023;23(1):24–37.PubMedCrossRef
80.
Krabbendam L, Bal SM, Spits H, Golebski K. New insights into the function, development, and plasticity of type 2 innate lymphoid cells. Immunol Rev. 2018;286(1):74–85.PubMedCrossRef
81.
Ito T, Wang YH, Duramad O, Hori T, Delespesse GJ, Watanabe N, et al. TSLP-activated dendritic cells induce an inflammatory T helper type 2 cell response through OX40 ligand. J Exp Med. 2005;202(9):1213–23.PubMedPubMedCentralCrossRef
82.
Gauvreau GM, Sehmi R, Ambrose CS, Griffiths JM. Thymic stromal lymphopoietin: its role and potential as a therapeutic target in asthma. Expert Opin Ther Targets. 2020;24(8):777–92.PubMedCrossRef
83.
Tanaka J, Watanabe N, Kido M, Saga K, Akamatsu T, Nishio A, et al. Human TSLP and TLR3 ligands promote differentiation of Th17 cells with a central memory phenotype under Th2-polarizing conditions. Clin Exp Allergy. 2009;39(1):89–100.PubMedCrossRef
84.
Gao H, Ying S, Dai Y. Pathological roles of neutrophil-mediated inflammation in asthma and its potential for therapy as a target. J Immunol Res. 2017;2017:3743048.PubMedPubMedCentralCrossRef
85.
86.
Corren J, Parnes JR, Wang L, Mo M, Roseti SL, Griffiths JM, et al. Tezepelumab in adults with uncontrolled asthma. N Engl J Med. 2017;377(10):936–46.PubMedCrossRef
87.
Menzies-Gow A, Corren J, Bourdin A, Chupp G, Israel E, Wechsler ME, et al. Tezepelumab in adults and adolescents with severe, uncontrolled asthma. N Engl J Med. 2021;384(19):1800–9.PubMedCrossRef
88.
Brusselle G, Riemann S. Is efficacy of tezepelumab independent of severe asthma phenotype? Am J Respir Crit Care Med. 2023.
89.
Trail.GOV C. Extension Study to Evaluate the Safety and Tolerability of Tezepelumab in Adults and Adolescents With Severe, Uncontrolled Asthma (DESTINATION) [Available from: Extension Study to Evaluate the Safety and Tolerability of Tezepelumab in Adults and Adolescents With Severe, Uncontrolled Asthma—Study Results—ClinicalTrials.gov.
90.
Shinkai M, Ebisawa M, Fukushima Y, Takeuchi S, Okada H, Tokiyo T, Hayashi N, Takikawa M, Colice G, Almqvist G. One-year safety and tolerability of tezepelumab in Japanese patients with severe uncontrolled asthma: results of the NOZOMI study. J Asthma. 2023;60(3):616–24. https://​doi.​org/​10.​1080/​02770903.​2022.​2082309
91.
Flokstra-de Blok B, Kocks J, Wouters H, Arling C, Chatelier J, Douglass J, et al. Perceptions on home-administration of biologics in the context of severe asthma: an international qualitative study. J Allergy Clin Immunol Pract. 2022;10(9):2312-23.e2.PubMedCrossRef
92.
Bel EH, I Bernstein D, Bjermer L, Follows R, Bentley JH, Pouliquen I, et al. Usability of mepolizumab single-use prefilled syringe for patient self-administration. J Asthma. 2020;57(7):755–64.
93.
Bernstein D, Pavord ID, Chapman KR, Follows R, Bentley JH, Pouliquen I, et al. Usability of mepolizumab single-use prefilled autoinjector for patient self-administration. J Asthma. 2020;57(9):987–98.PubMedCrossRef
94.
Alpizar S, Megally A, Chen C, Raj A, Downie J, Colice G. Functionality and performance of an accessorized pre-filled syringe and an autoinjector for at-home administration of tezepelumab in patients with severe, uncontrolled asthma. J Asthma Allergy. 2021;14:381–92.PubMedPubMedCentralCrossRef
95.
Makhecha S, Jamalzadeh A, Irving S, Hall P, Sonnappa S, Saglani S, et al. Paediatric severe asthma biologics service: from hospital to home. Arch Dis Child. 2021;106(9):900–2.PubMedCrossRef
96.
Albers FC, Licskai C, Chanez P, Bratton DJ, Bradford ES, Yancey SW, et al. Baseline blood eosinophil count as a predictor of treatment response to the licensed dose of mepolizumab in severe eosinophilic asthma. Respir Med. 2019;159: 105806.PubMedCrossRef
97.
Akenroye A, Lassiter G, Jackson JW, Keet C, Segal J, Alexander GC, et al. Comparative efficacy of mepolizumab, benralizumab, and dupilumab in eosinophilic asthma: A Bayesian network meta-analysis. J Allergy Clin Immunol. 2022;150(5):1097-105.e12.PubMedPubMedCentralCrossRef
98.
Li Y, Li X, Zhang B, Yu Q, Lu Y. Predictive biomarkers for response to omalizumab in patients with severe allergic asthma: a meta-analysis. Expert Rev Respir Med. 2022;16(9):1023–33.PubMedCrossRef
99.
Pavord ID, Deniz Y, Corren J, Casale TB, FitzGerald JM, Izuhara K, et al. Baseline FeNO independently predicts the dupilumab response in patients with moderate-to-severe asthma. J Allergy Clin Immunol Pract. 2022.
100.
Hearn AP, Kavanagh J, d’Ancona G, Roxas C, Green L, Thomson L, et al. The relationship between Feno and effectiveness of mepolizumab and benralizumab in severe eosinophilic asthma. J Allergy Clin Immunol Pract. 2021;9(5):2093-6.e1.PubMedCrossRef
101.
Dweik RA, Boggs PB, Erzurum SC, Irvin CG, Leigh MW, Lundberg JO, et al. An official ATS clinical practice guideline: interpretation of exhaled nitric oxide levels (FENO) for clinical applications. Am J Respir Crit Care Med. 2011;184(5):602–15.PubMedPubMedCentralCrossRef
102.
103.
Takahashi K, Meguro K, Kawashima H, Kashiwakuma D, Kagami SI, Ohta S, et al. Serum periostin levels serve as a biomarker for both eosinophilic airway inflammation and fixed airflow limitation in well-controlled asthmatics. J Asthma. 2019;56(3):236–43.PubMedCrossRef
104.
Mansur AH, Srivastava S, Sahal A. Disconnect of type 2 biomarkers in severe asthma; dominated by FeNO as a predictor of exacerbations and periostin as predictor of reduced lung function. Respir Med. 2018;143:31–8.PubMedCrossRef
105.
Kashima TG, Nishiyama T, Shimazu K, Shimazaki M, Kii I, Grigoriadis AE, et al. Periostin, a novel marker of intramembranous ossification, is expressed in fibrous dysplasia and in c-Fos-overexpressing bone lesions. Hum Pathol. 2009;40(2):226–37.PubMedCrossRef
106.
107.
Demarche S, Schleich F, Henket M, Paulus V, Van Hees T, Louis R. Detailed analysis of sputum and systemic inflammation in asthma phenotypes: are paucigranulocytic asthmatics really non-inflammatory? BMC Pulm Med. 2016;16:46.PubMedPubMedCentralCrossRef
108.
Agache I, Ciobanu C, Agache C, Anghel M. Increased serum IL-17 is an independent risk factor for severe asthma. Respir Med. 2010;104(8):1131–7.PubMedCrossRef
109.
Gibson PG, Simpson JL, Saltos N. Heterogeneity of airway inflammation in persistent asthma : evidence of neutrophilic inflammation and increased sputum interleukin-8. Chest. 2001;119(5):1329–36.PubMedCrossRef
110.
Wood LG, Baines KJ, Fu J, Scott HA, Gibson PG. The neutrophilic inflammatory phenotype is associated with systemic inflammation in asthma. Chest. 2012;142(1):86–93.PubMedCrossRef
111.
O’Byrne PM, Panettieri RA Jr, Taube C, Brindicci C, Fleming M, Altman P. Development of an inhaled anti-TSLP therapy for asthma. Pulm Pharmacol Ther. 2023;78: 102184.PubMedCrossRef
112.
113.
Richards LB, van Bragt J, Aarab R, Longo C, Neerincx AH, Sont JK, et al. Treatment eligibility of real-life mepolizumab-treated severe asthma patients. J Allergy Clin Immunol Pract. 2020;8(9):2999-3008.e1.PubMedCrossRef
114.
Nieto García A, Garriga-Baraut T, Plaza Martín AM, Nieto Cid M, Torres Borrego J, FolquéGiménez MDM, et al. Omalizumab outcomes for up to 6 years in pediatric patients with severe persistent allergic asthma. Pediatr Allergy Immunol. 2021;32(5):980–91.PubMedCrossRef
115.
Jackson DJ, Bacharier LB, Gergen PJ, Gagalis L, Calatroni A, Wellford S, et al. Mepolizumab for urban children with exacerbation-prone eosinophilic asthma in the USA (MUPPITS-2): a randomised, double-blind, placebo-controlled, parallel-group trial. Lancet. 2022;400(10351):502–11.PubMedPubMedCentralCrossRef
116.
Coleman C, Khaleva E, Rattu A, Frankemölle B, Nielsen H, Roberts G, et al. Narrative review to capture patients' perceptions and opinions about non-response and response to biological therapy for severe asthma. Eur Resp J. 2023;61(1).
117.
Lanario JW, Burns L. Use of health related quality of life in clinical trials for severe asthma: a systematic review. J Asthma Allergy. 2021;14:999–1010.PubMedPubMedCentralCrossRef
118.
Clark VL, Gibson PG, McDonald VM. What matters to people with severe asthma? Exploring add-on asthma medication and outcomes of importance. ERJ Open Res. 2021;7(1).
119.
Clark VL, Gibson PG, McDonald VM. The patients’ experience of severe asthma add-on pharmacotherapies: a qualitative descriptive study. J Asthma Allergy. 2021;14:245–58.PubMedPubMedCentralCrossRef
120.
de Graaff MB, Bendien SA, van de Bovenkamp HM. “Like a fish on dry land”: an explorative qualitative study into severe asthma and the impact of biologicals on patients’ everyday life. J Asthma. 2022;59(5):980–8.PubMedCrossRef
121.
122.
Saglani S, Bush A, Carroll W, Cunningham S, Fleming L, Gaillard E, et al. Biologics for paediatric severe asthma: trick or TREAT? Lancet Respir Med. 2019;7(4):294–6.PubMedCrossRef
123.
Scioscia G, Nolasco S, Campisi R, Quarato CMI, Caruso C, Pelaia C, et al. Switching biological therapies in severe asthma. Int J Mol Sci. 2023;24(11).
124.
Deschildre A, Roussel J, Drumez E, Abou-Taam R, Rames C, Le Roux P, et al. Omalizumab discontinuation in children with severe allergic asthma: an observational real-life study. Allergy. 2019;74(5):999–1003.PubMedCrossRef
125.
Jeffery MM, Inselman JW, Maddux JT, Lam RW, Shah ND, Rank MA. Asthma patients who stop asthma biologics have a similar risk of asthma exacerbations as those who continue asthma biologics. J Allergy Clin Immunol Pract. 2021;9(7):2742-50.e1.PubMedPubMedCentralCrossRef
126.
Khaleva E, Rattu A, Brightling C, Bush A, Bossios A, Bourdin A, et al. Development of Core Outcome Measures sets for paediatric and adult Severe Asthma (COMSA). Eur Resp J. 2022.
127.
Golebski K, Kabesch M, Melén E, Potočnik U, van Drunen CM, Reinarts S, et al. Childhood asthma in the new omics era: challenges and perspectives. Curr Opin Allergy Clin Immunol. 2020;20(2):155–61.PubMedCrossRef
128.
Carraro S, di Palmo E, Licari A, Barni S, Caldarelli V, De Castro G, et al. Metabolomics to identify omalizumab responders among children with severe asthma: a prospective study. Allergy. 2022;77(9):2852–6.PubMedCrossRef
129.
Wechsler ME, Ford LB, Maspero JF, Pavord ID, Papi A, Bourdin A, et al. Long-term safety and efficacy of dupilumab in patients with moderate-to-severe asthma (TRAVERSE): an open-label extension study. Lancet Respir Med. 2022;10(1):11–25.PubMedCrossRef
130.
Menzies-Gow A, Ponnarambil S, Downie J, Bowen K, Hellqvist Å, Colice G. DESTINATION: a phase 3, multicentre, randomized, double-blind, placebo-controlled, parallel-group trial to evaluate the long-term safety and tolerability of tezepelumab in adults and adolescents with severe, uncontrolled asthma. Respir Res. 2020;21(1):279.PubMedPubMedCentralCrossRef
Metadata
Title
Developments in the Management of Severe Asthma in Children and Adolescents: Focus on Dupilumab and Tezepelumab
Authors
Yoni E. van Dijk
Niels W. Rutjes
Korneliusz Golebski
Havva Şahin
Simone Hashimoto
Anke-Hilse Maitland-van der Zee
Susanne J. H. Vijverberg
Publication date
02-09-2023
Publisher
Springer International Publishing
Published in
Pediatric Drugs / Issue 6/2023
Print ISSN: 1174-5878
Electronic ISSN: 1179-2019
DOI
https://doi.org/10.1007/s40272-023-00589-4

Other articles of this Issue 6/2023

Pediatric Drugs 6/2023 Go to the issue

Original Research Article

Azacitidine (Vidaza®) in Pediatric Patients with Relapsed Advanced MDS and JMML: Results of a Phase I/II Study by the ITCC Consortium and the EWOG-MDS Group (Study ITCC-015)

Review Article

Hidradenitis Suppurativa in Children and Adolescents: An Update on Pharmacologic Treatment Options

Leading Article

Use of JAK inhibitors in children

Leading Article

Managing patients with systemic JIA and lung disease

AdisInsight Report

Respiratory Syncytial Virus Prefusion F Subunit Vaccine: First Approval of a Maternal Vaccine to Protect Infants

Original Research Article

Impact of Dexmedetomidine Infusion on Opioid and Benzodiazepine Doses in Ventilated Pediatric Patients in the Cardiac Intensive Care Unit